EDN2 | |||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
Aliases | EDN2, ET2, PPET2, ET-2, endothelin 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||
External IDs | OMIM: 131241; MGI: 95284; HomoloGene: 1477; GeneCards: EDN2; OMA:EDN2 - orthologs | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
Endothelin 2 (ET-2) is a protein encoded by the EDN2 gene in humans. It was first discovered in 1988 by Yanagisawa and team[5] and belongs to a family of three endothelin peptide isoforms (ET-1, ET-2, ET-3), which constrict blood vessels. ET-2 is encoded by genes on separate chromosomes to its isoforms and is mainly produced in vascular endothelial cells of the kidney, placenta, uterus, heart, central nervous system and intestine.[6] It becomes present in the blood of animals and humans at levels ranging from 0.3pg/ml to 3pg/ml.[7] ET-2 acts by binding to two different G-protein coupled receptors (GPCRs), the endothelin A receptor (EDNRA) and the endothelin B receptor (EDNRB).[8]
Function
[edit]As ET-2 has a very similar homology to ET-1, differing only in two amino acids (with Trp6 and Leu7 instead of Leu6 and Met7[7]) it was often assumed that the two endothelins were similar in synthetic pathway and mechanism of action.[9] As ET-1 is abundant in the body while ET-2 is almost undetectable, ET-1 was more convenient to research, this assumption has meant ET-2 is relatively under-researched. Equally, limited studies have been conducted using VIC, a vasoactive intestinal peptide and the peptide equivalent to ET-2 in mice.[7]
However, further research evidence suggested distinct roles and features of ET-2. Unlike the other endothelins, ET-2 knockout mice (with the EDN2 gene globally removed from their genetic code) are retarded in growth, hypoglycemic, hypothermic and have ketonemia, resulting in early mortality. These differences between ET-1 and ET-2 may be attributed to differing gene expression and the synthesis of different peptides by endothelin converting enzymes (ECEs).[7]
ET-2 is a potent vasoconstrictor and has been implicated in ovarian physiology, as well as diseases relating to the heart, immunology, and cancers.[7]
Clinical significance
[edit]Ovarian follicle rupture
[edit]Ovulation occurs at around day 14 of the human menstrual cycle and refers to the release of an egg, characterised by the rupture of a preovulatory ovarian follicle. This process is driven changes in oestrogen-regulated feedback on the hypothalamic-pituitary-gonadal axis, leading to a surge of Luteinising Hormone which drives follicular rupture.[10] There is a complex molecular dialogue for ovulation which involves the coordinated expression of many key proteins, including ET-2.[11]
Within the follicle, ET-2 expression is confined to a group of steroid-producing stromal cells called granulosa cells, where its production peaks transiently at the final stages before ovulation (periovulatory stage). In the mouse, there is a surge of ET-2 around two hours prior to ovulation, this is thought to act as one of the driving forces for follicular rupture. Much of our current understanding of ET-2 and its role during ovulation comes from rodent model experiments. However, there are some interspecies discrepancies, with stark differences identified between the mouse and bovine ovary.[7]
The mechanisms underlying ET-2-induced follicle rupture are debated, with most theories suggesting a mechanical contraction pathway. ET-2 is believed to act on the follicle by binding to and stimulating EDNRA, which is expressed constitutively on the external layer of theca cells (another type of steroid-producing stromal cell). This causes smooth muscle cells surrounding the ovary to contract.[11] This smooth muscle layer encapsulates the ovary but is absent at the site where the oocyte is expelled, creating a region of low surface tension which weakens the follicle wall and promotes the release of an egg.[7]
ET-2 also binds to and activates EDNRB, which is constitutively expressed by granulosa cells and theca interna. There is controversy surrounding the role of ET-2 signalling at this receptor. Some studies suggest that EDNRB activation by ET-2 regulates follicular rupture by antagonising effects of EDNRA stimulation. Alternatively, EDNRB may propel follicular rupture by inducing nitric oxide signalling. This results in local vasodilation, contributing to the rise in follicular fluid pressure seen in the periovulatory phase.[11]
Cardiovascular system
[edit]ET-2, like ET-1, has a role in modulating vascular tone.[7] This can have implications for blood pressure control. A specific EDN2 gene polymorphism has been correlated with essential hypertension and alternative studies have shown associations between certain rare ET-2 polymorphisms and lower diastolic blood pressures.[7] The ET-2 gene has been shown to co-segregate with blood pressure in rodent studies; a potential reason for the link.[12]
However, transgenic rats expressing the human ET-2 gene under the control of the human endothelin promotor are normotensive (blood pressure in normal range), despite these studies suggesting that overexpression of ET-2 results in glomerulosclerosis.[7][12] This suggests that further investigation into the role of ET-2 in blood pressure is warranted.
As a strong positive inotrope, endothelin-2 has an impact on the human myocardium and for this reason, endothelin-2 antagonists have been shown to improve exercise tolerance and inhibit clinical deterioration in pulmonary hypertension.[7] ET-2 demonstrates a positive chronotropic and proarrhythmic effects. A study showed a significant association of a specific polymorphism of the EDN2 gene with increased incidence of atrial fibrillation in patients with hypertrophic cardiomyopathy.[12] Overall, the evidence suggests that ET-2 could modulate vascular tone, tissue morphology and remodelling.[12]
Breast tumour cell invasion
[edit]Since reports of increased ET-2 expression in human breast cancer (2002), there has been growing interest in ET-2 within cancer pathogenesis.[7] There is increased expression of the ‘endothelin axis’ consisting of 21 amino acid peptides (ET-1, ET-2 and ET-3), two GPCRs and two activating peptidases in invasive breast cancer.[13] This increased expression is not seen in non-invasive tissue.[13] This is further supported by observations from patient biopsies, endothelin expression is associated specifically with regions of the tumour that are invasive and is more common in whole tumours with lymphovascular invasion (i.e. the invasion of cancer cells into the lymphatic system).[13]
In vitro, when breast tumour cell lines with endothelins are stimulated, the phenotype becomes invasive.[13] Invasion through an artificial membrane can be stimulated, particularly when co-cultured in the presence of macrophages.[13] The association between endothelins, poor prognosis and invasion suggests the endothelin axis is an interesting therapeutic target for the treatment of invasive breast cancer.[13]
The breast tumour microenvironment is particularly hypoxic which allows it to modulate the expression of numerous ‘pro-tumour’ genes including endothelins. This hypoxic environment can be replicated in vitro, resulting in increased expression of ET-2 by breast tumour cells.[13] This increased ET-2 expression provides the tumour with autocrine protection from hypoxia-associated apoptosis allowing growth of the tumour.[13] Further research using mice with breast tumours in hypoxic conditions showed that the addition of ET-2 increased the survival of tumour cells suggesting the upregulation of ET-2 in hypoxic tumours may explain the increased invasive potential and worse prognosis than their well oxygenated counterparts.[7]
References
[edit]- ^ a b c GRCh38: Ensembl release 89: ENSG00000127129 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000028635 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. (March 1988). "A novel potent vasoconstrictor peptide produced by vascular endothelial cells" (PDF). Nature. 332 (6163): 411–5. Bibcode:1988Natur.332..411Y. doi:10.1038/332411a0. hdl:2241/1639. PMID 2451132. S2CID 4308549.
- ^ Vatta MS, Bianciotti LG, Guil MJ, Hope SI (2015). "Regulation of the norepinephrine transporter by endothelins: a potential therapeutic target". Vitamins and Hormones. 98: 371–405. doi:10.1016/bs.vh.2014.12.013. hdl:11336/38984. ISBN 978-0-12-803008-0. PMID 25817875.
- ^ a b c d e f g h i j k l m Ling L, Maguire JJ, Davenport AP (January 2013). "Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer". British Journal of Pharmacology. 168 (2): 283–95. doi:10.1111/j.1476-5381.2011.01786.x. PMC 3572556. PMID 22118774.
- ^ Nakas-Ićindić E, Zaciragić A, Hadzović A, Avdagić N (July 2004). "Endothelin in health and disease". Bosnian Journal of Basic Medical Sciences. 4 (3): 31–4. doi:10.17305/bjbms.2004.3381. PMC 7245481. PMID 15629009.
- ^ Binz N, Rakoczy EP, Ali Rahman IS, Vagaja NN, Lai CM (2016-08-02). Knut S (ed.). "Biomarkers for Diabetic Retinopathy - Could Endothelin 2 Be Part of the Answer?". PLOS ONE. 11 (8): e0160442. Bibcode:2016PLoSO..1160442B. doi:10.1371/journal.pone.0160442. PMC 4970817. PMID 27482904.
- ^ Robker RL, Hennebold JD, Russell DL (September 2018). "Coordination of Ovulation and Oocyte Maturation: A Good Egg at the Right Time". Endocrinology. 159 (9): 3209–3218. doi:10.1210/en.2018-00485. PMC 6456964. PMID 30010832.
- ^ a b c Ko C, Meidan R, Bridges PJ (October 2012). "Why two endothelins and two receptors for ovulation and luteal regulation?". Life Sciences. 91 (13–14): 501–6. doi:10.1016/j.lfs.2012.05.010. PMID 22677434.
- ^ a b c d Krämer BK, Ittner KP, Beyer ME, Hoffmeister HM, Riegger GA (1997-11-01). "Circulatory and myocardial effects of endothelin". Journal of Molecular Medicine. 75 (11–12): 886–90. doi:10.1007/s001090050180. PMID 9428621. S2CID 8300313.
- ^ a b c d e f g h Grimshaw MJ (May 2005). "Endothelins in breast tumour cell invasion". Cancer Letters. 222 (2): 129–38. doi:10.1016/j.canlet.2004.08.029. PMID 15863261.
Further reading
[edit]- Arjomand-Nahad F, Landt O, Stangl K, Diefenbach K, Roots I (2006). "Fifteen polymorphisms in endothelin-1, endothelin-2 and endothelin-receptor-A genotyped by four duplex assays and seven simple assays on a LightCycler using hybridization probes". Clinical Chemistry and Laboratory Medicine. 44 (8): 929–32. doi:10.1515/CCLM.2006.180. PMID 16879056. S2CID 427362.
- Ryckman KK, Morken NH, White MJ, Velez DR, Menon R, Fortunato SJ, et al. (February 2010). "Maternal and fetal genetic associations of PTGER3 and PON1 with preterm birth". PLOS ONE. 5 (2): e9040. Bibcode:2010PLoSO...5.9040R. doi:10.1371/journal.pone.0009040. PMC 2815792. PMID 20140262.
- Dimoulios P, Kolios G, Notas G, Matrella E, Xidakis C, Koulentaki M, et al. (February 2005). "Ursodeoxycholic acid reduces increased circulating endothelin 2 in primary biliary cirrhosis". Alimentary Pharmacology & Therapeutics. 21 (3): 227–34. doi:10.1111/j.1365-2036.2005.02307.x. PMID 15691296. S2CID 23611082.
- Menon R, Pearce B, Velez DR, Merialdi M, Williams SM, Fortunato SJ, Thorsen P (June 2009). "Racial disparity in pathophysiologic pathways of preterm birth based on genetic variants". Reproductive Biology and Endocrinology. 7: 62. doi:10.1186/1477-7827-7-62. PMC 2714850. PMID 19527514.
- Kotake-Nara E, Saida K (February 2006). "Endothelin-2/vasoactive intestinal contractor: regulation of expression via reactive oxygen species induced by CoCl2, and Biological activities including neurite outgrowth in PC12 cells". TheScientificWorldJournal. 6: 176–86. doi:10.1100/tsw.2006.37. PMC 5917238. PMID 16493522.
- Paulino EC, Steil AA, Jancar S (July 2006). "Effect of endothelins on human neutrophil activation by immune complexes". International Immunopharmacology. 6 (7): 1119–25. doi:10.1016/j.intimp.2006.01.022. PMID 16714215.
- Velez DR, Fortunato SJ, Thorsen P, Lombardi SJ, Williams SM, Menon R (September 2008). "Preterm birth in Caucasians is associated with coagulation and inflammation pathway gene variants". PLOS ONE. 3 (9): e3283. Bibcode:2008PLoSO...3.3283V. doi:10.1371/journal.pone.0003283. PMC 2553267. PMID 18818748.
- Dagle JM, Lepp NT, Cooper ME, Schaa KL, Kelsey KJ, Orr KL, et al. (April 2009). "Determination of genetic predisposition to patent ductus arteriosus in preterm infants". Pediatrics. 123 (4): 1116–23. doi:10.1542/peds.2008-0313. PMC 2734952. PMID 19336370.
- Wiesmann F, Veeck J, Galm O, Hartmann A, Esteller M, Knüchel R, Dahl E (2009). "Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer". Breast Cancer Research. 11 (3): R34. doi:10.1186/bcr2319. PMC 2716502. PMID 19527488.
- Meidan R, Levy N (December 2007). "The ovarian endothelin network: an evolving story". Trends in Endocrinology and Metabolism. 18 (10): 379–85. doi:10.1016/j.tem.2007.09.002. PMID 17997104. S2CID 44415810.
- Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, et al. (November 2009). "Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip". American Journal of Human Genetics. 85 (5): 628–42. doi:10.1016/j.ajhg.2009.10.014. PMC 2775832. PMID 19913121.
- Rebourcet R, Mignot TM, Robert B, Ferré F (2004). "Endothelin-2 down-regulation occurs in parallel with the anti-proliferative effect of dimethylsulfoxide in BeWO human choriocarcinoma cell line". Cellular and Molecular Biology. 50 Online Pub: OL701-12. PMID 15619356.
- Nagai T, Ogimoto A, Okayama H, Ohtsuka T, Shigematsu Y, Hamada M, et al. (December 2007). "A985G polymorphism of the endothelin-2 gene and atrial fibrillation in patients with hypertrophic cardiomyopathy". Circulation Journal. 71 (12): 1932–6. doi:10.1253/circj.71.1932. PMID 18037749.
- Velez DR, Fortunato S, Thorsen P, Lombardi SJ, Williams SM, Menon R (February 2009). "Spontaneous preterm birth in African Americans is associated with infection and inflammatory response gene variants". American Journal of Obstetrics and Gynecology. 200 (2): 209.e1–27. doi:10.1016/j.ajog.2008.08.051. PMC 4829203. PMID 19019335.
- Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR (April 2004). "A role for endothelin-2 and its receptors in breast tumor cell invasion". Cancer Research. 64 (7): 2461–8. doi:10.1158/0008-5472.can-03-1069. PMID 15059899.
- Dowal L, Provitera P, Scarlata S (August 2006). "Stable association between G alpha(q) and phospholipase C beta 1 in living cells". The Journal of Biological Chemistry. 281 (33): 23999–4014. doi:10.1074/jbc.M512330200. PMID 16754659.
- Sun DJ, Liu Y, Lu DC, Kim W, Lee JH, Maynard J, Deisseroth A (July 2007). "Endothelin-3 growth factor levels decreased in cervical cancer compared with normal cervical epithelial cells". Human Pathology. 38 (7): 1047–56. doi:10.1016/j.humpath.2006.12.015. PMID 17445867.
- Darrah R, McKone E, O'Connor C, Rodgers C, Genatossio A, McNamara S, et al. (March 2010). "EDNRA variants associate with smooth muscle mRNA levels, cell proliferation rates, and cystic fibrosis pulmonary disease severity". Physiological Genomics. 41 (1): 71–7. doi:10.1152/physiolgenomics.00185.2009. PMC 2841492. PMID 20028935.
- Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, et al. (October 2010). "Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study". Diabetes Care. 33 (10): 2250–3. doi:10.2337/dc10-0452. PMC 2945168. PMID 20628086.
- Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, et al. (April 2016). "Endothelin". Pharmacological Reviews. 68 (2): 357–418. doi:10.1124/pr.115.011833. PMC 4815360. PMID 26956245.